tbuckley/cabot-search huggingface dataset:
CXCR7 Expression Restricts CXCR4/SDF-1 Mediated Hematopoietic-Supporting Activity of Stromal Cells by Decreasing Extracellular SDF-1 Availability.
Authors: Hakim Bouamar, Yanyan Zhang, Dima Jouni, Monika Wittner, Morad Bensidhoum, Peggy Jarrier, Hervé Petite, William Vainchenker, Olivier Albagli, Fawzia Louache
Journal: Blood (2009)
Comprehensive Geriatric Assessment-Adapted Chemotherapy in 100 Elderly Patients (&gt;70 Years) with Diffuse Large B-Cell Non-Hodgkin’s Lymphoma (DLBCL).
Authors: Michele Spina, Monica Balzarotti, Uziel Lilj, Ferreri Andres, Fratino Lucia, Santoro Armando, Tirelli Umberto
Journal: Blood (2006)
YM155 Exerts Potent Cytotoxic Activity Against Quiescent (G0/G1) Multiple Myeloma and Bortezomib Resistant Cells Via Inhibition of Mcl-1 and Survivin
Authors: Miyuki Ookura, Tatsuya Fujii, Shinji Kishi, Hiroko Shigemi, Naoko Hosono, Takahiro Yamauchi, Takanori Ueda, Akira Yoshida
Journal: Blood (2015)
Cost-Effectiveness of Posaconazole Versus Standard Azole Therapy in the Prevention of Invasive Fungal Infections among High-Risk Neutropenic Patients in the U.S.
Authors: Amy K. O’Sullivan, Ankur Pandya, David Thompson, George Papadopoulos, Milton C. Weinstein, John R. Perfect, Amelia Langston
Journal: Blood (2006)
The immunoglobulin superfamily member <scp>CD</scp>200R identifies cells involved in type 2 immune responses
Authors: L. H. Blom, B. C. Martel, L. F. Larsen, C. V. Hansen, M. P. Christensen, N. Juel‐Berg, T. Litman, L. K. Poulsen
Journal: Allergy (2017)

Abstract Background The pathology of allergic diseases involves type 2 immune cells, such as Th2, ILC 2, and basophils exerting their effect by production of IL ‐4, IL ‐5, and IL ‐13. However, surface receptors that are specifically expressed on type 2 immune cells are less well documented. The aim of this investigation was to identify surface markers associated with type 2 inflammation. Methods Naïve human CD 4 + T cells were short‐term activated in the presence or absence of IL ‐4 and analyzed for expression of &gt;300 cell‐surface proteins. Ex vivo ‐isolated peripheral blood mononuclear cells ( PBMC s) from peanut‐allergic ( PA ) and nonallergic subjects were stimulated (14–16 h) with peanut extract to detect peanut‐specific CD 4 + CD 154 + T cells. Biopsies were obtained for transcriptomic analysis from healthy controls and patients with extrinsic or intrinsic atopic dermatitis (AD) and psoriasis. Results Expression analysis of &gt;300 surface proteins enabled identification of IL ‐4‐upregulated surface proteins, such as CD 90, CD 108, CD 109, and CD 200R ( CD 200R1). Additional analysis of in vitro ‐differentiated Th0, Th1, and Th2 cultures identified CD 200R as upregulated on Th2 cells. From ex vivo ‐isolated PBMC s, we found high expression of CD 200R on Th2 and ILC 2 cells and basophils. In PA subjects, the peanut‐specific Th2 ( CD 154 + CRT h2 + ) cells expressed more CD 200R than the non‐allergen‐specific Th2 ( CD 154 − CRT h2 + ) cells. Moreover, costaining of CD 161 and CD 200R identified peanut‐specific highly differentiated IL ‐4 + IL ‐5 + Th2 cells. Finally, transcriptomic analysis revealed upregulation of CD 200R in lesional skin from subjects with an extrinsic AD phenotype compared to healthy skin. Conclusion These results indicate that CD 200R expression strongly correlates with Th2 pathology; though, the mechanism is as yet elusive.
Epigenetic Therapy Inhibits NUP98-HOXA9-Mediated Myeloid Disease – Decitabine and Valproic Acid Work Synergistically to Rescue Normal Hematopoiesis in Transgenic Zebrafish.
Authors: Adam Deveau, A. Michael Forrester, Clemens Grabher, Andrew J Coombs, Ian Chute, Daniel Leger, Stephen Lewis, A. Thomas Look, Jason N Berman
Journal: Blood (2012)
The Pim Kinase Inhibitor AZD1208 Enhances Topoisomerase-2 Inhibitor Induction of Apoptosis of Acute Myeloid Leukemia Cells with FLT3-ITD through Increased Oxidative Stress
Authors: Kshama A. Doshi, Karthika Natarajan, Feyruz V. Rassool, Dennis Huszar, Maria R. Baer
Journal: Blood (2015)
Up-Regulation of Hexokinase II (HK) Alters the Glucose Metabolism and Disrupts the Mitochondrial Potential in Aggressive B-Cell Lymphoma Contributing to Rituximab-Chemotherapy Resistance and Is a Clinically Relevant Target for Future Therapeutic Development
Authors: Juan J Gu, Anil Singh, Cory Mavis, Vivek Yanamadala, Kai Xue, Michael Grau, Peter Lenz, Georg Lenz, Myron S. Czuczman, Francisco Hernandez
Journal: Blood (2014)
Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial
Authors: Francisco M Marty, Joan Vidal-Puigserver, Carol Clark, Sandeep K Gupta, Esperanza Merino, Denis Garot, Marianne J Chapman, Frédérique Jacobs, Eduardo Rodriguez-Noriega, Petr Husa, Denise Shortino, Helen A Watson, Phillip J Yates, Amanda F Peppercorn
Journal: The Lancet Respiratory Medicine (2017)
Fever Following Bortezomib Administration Correlated with Serum Cytokine Levels in Patients with Multiple Myeloma (MM).
Authors: Dai Maruyama, Takashi Watanabe, Fusako Ohara, Kazuki Tanimoto, Sung-Won Kim, Satoshi Yamasaki, Yuriko Morita, Yukio Kobayashi, Kensei Tobinai
Journal: Blood (2006)
Expression of the BAFF-R (BR3) Is Positive in a Minority of Diffuse Large B Cell Lymphomas and Does Not Correlate with the Germinal Center or Non Germinal Center Origin of Lymphomatous Cells.
Authors: Alexis Proust, Idir Adrar, Patricia Rince, Virginie Mercier, Thierry Lazure, Martine Raphael, Loïc Garçon
Journal: Blood (2005)
Diversity without Limits: New Insights from the Most Comprehensive Tree of Prokaryotic Life Assembled To Date
Authors: Joseph Caspermeyer
Journal: Molecular Biology and Evolution (2016)

Bacteria were the original masters of their domain, having the Earth to themselves for the majority of their existence, filling every environmental niche, nook and cranny, from mountain peaks to the thermal vents at the ocean's floor.Now, Marin et al. have completed a new tree of prokaryotic life calibrated to time, assembled from 11,784 species of bacteria.The new tree explores grand patterns of evolutionary change that, surprisingly, has revealed remarkable similarities with that of eukaryotes, including animals, plants, and fungi.With widespread rapid and low-cost sequencing available, the branches in the tree of life have grown ever more detailed and scientists can more readily uncover macroevolutionary forces at work.Relying on data from the small subunit ribosomal RNA of bacteria, researchers at Temple University's Center for Biodiversity, including
Incidence and Clinicopathological Relevance of Gene Copy Number Abnormalities Detected by a Single Quantitative PCR Assay in Mantle Cell Lymphomas.
Authors: Fabrice Jardin, Jean-Michel Picquenot, Francoise Parmentier, Marie Cornic, Sandrine Vaudaux, Philippe Ruminy, Dominique Penther, Helene Lanic, Ophelie Cassuto, Vincianne Rainville, Christian Bastard, Herve Tilly
Journal: Blood (2008)
CD81: A Novel, Specific and Highly Sensitive Marker in Flow Cytometric Diagnosis of Plasma Cell Dyscrasia
Authors: Prashant Ramesh Tembhare, Constance Yuan, Neha Korde, Irina Maric, Katherine Calvo, Mary Ann Yancey, Marcia Mulquin, Ola Landgren, Maryalice Stetler-Stevenson
Journal: Blood (2011)
Alpha-Tocopherol Induces Apoptosis in Acute Promyelocytic Leukemia Cells through a P53-Independent Pathway.
Authors: Rosana A. Freitas, Ana Silvia G. Lima, Aglair B. Garcia, Hamilton L.G. Teixeira, Rodrigo S.A. Lima, Monica S.S. Meirelles, Helio Vannucchi, Roberto P. Falcao, Eduardo M. Rego
Journal: Blood (2004)
Tissue Factor Enriched Microvesicles Plus Factor VIIa Induce Platelet Aggregation in the Absence of Coagulation Proteins: Evidence for the Involvement of Internalization and Trafficking Mechanisms.
Authors: Irene Lopez-Vilchez, Gines Escolar, Maribel Diaz-Ricart, Ana M. Galan, Nuria Cortadellas, James G. White
Journal: Blood (2005)
Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials
Authors: Sripal Bangalore, Robert Fakheri, Simon Wandel, Bora Toklu, Jasmin Wandel, Franz H Messerli
Journal: BMJ (2017)

<b>Objective</b>&nbsp;To critically evaluate the efficacy of renin angiotensin system inhibitors (RASi) in patients with coronary artery disease without heart failure, compared with active controls or placebo. <b>Design</b>&nbsp;Meta-analysis of randomized trials. <b>Data sources</b>&nbsp;PubMed, EMBASE, and CENTRAL databases until 1 May 2016. <b>Eligibility criteria for selecting studies</b>&nbsp;Randomized trials of RASi versus placebo or active controls in patients with stable coronary artery disease without heart failure (defined as left ventricular ejection fraction ≥40% or without clinical heart failure). Each trial had to enroll at least 100 patients with coronary artery disease without heart failure, with at least one year’s follow-up. Studies were excluded if they were redacted or compared use of angiotensin converting enzyme inhibitors with angiotensin receptor blockers. Outcomes were death, cardiovascular death, myocardial infarction, angina, stroke, heart failure, revascularization, incident diabetes, and drug withdrawal due to adverse effects. <b>Results</b>&nbsp;24 trials with 198 275 patient years of follow-up were included. RASi reduced the risk of all cause mortality (rate ratio 0.84, 95% confidence interval 0.72 to 0.98), cardiovascular mortality (0.74, 0.59 to 0.94), myocardial infarction (0.82, 0.76 to 0.88), stroke (0.79, 0.70 to 0.89), angina, heart failure, and revascularization when compared with placebo but not when compared with active controls (all cause mortality, 1.05, 0.94 to 1.17; P<sub>interaction</sub>=0.006; cardiovascular mortality, 1.08, 0.93 to 1.25, P<sub>interaction</sub>&lt;0.001; myocardial infarction, 0.99, 0.87 to 1.12, P<sub>interaction</sub>=0.01; stroke, 1.10, 0.93 to 1.31; P<sub>interaction</sub>=0.002). Bayesian meta-regression analysis showed that the effect of RASi when compared with placebo on all cause mortality and cardiovascular mortality was dependent on the control event rate, such that RASi was only beneficial in trials with high control event rates (&gt;14.10 deaths and &gt;7.65 cardiovascular deaths per 1000 patient years) but not in those with low control event rates. <b>Conclusions</b>&nbsp;In patients with stable coronary artery disease without heart failure, RASi reduced cardiovascular events and death only when compared with placebo but not when compared with active controls. Even among placebo controlled trials in this study, the benefit of RASi was mainly seen in trials with higher control event rates but not in those with lower control event rates. Evidence does not support a preferred status of RASi over other active controls.
Concerns About Women’s Health
Authors: Jeff Lyon
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OBSTETRICS AND GYNÆCOLOGY.
Authors: Walter C Swayne
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
R-DHAOX as Salvage Regimen in Patients (pts) with Relapsed/Resistant Non-Hodgkin[spos]s Lymphoma (NHL).
Authors: Maurizio Rupolo, Michele Spina, Mariagrazia Michieli, Massimiliano Berretta, Luciano Abbruzzese, Mario Mazzucato, Valter Gattei, Umberto Tirelli
Journal: Blood (2004)
An Integrated Genomic Classification That Includes Copy Number Alterations Is Highly Predictive of Post Induction Minimal Residual Disease (MRD) Status in Childhood Precursor B Lineage Acute Lymphoblastic Leukemia
Authors: Nikhil Patkar, Papagudi Ganesan Subramanian, Prashant Tembhare, Pratibha Amare Kadam, Asma Bibi, Karishma Chopra, Satish Mirgal, Sagar Rambhiya, Swapnali Joshi, Shruti Chaudhary, Russel Mascrenhas, Sona Dusseja, Gaurav Narula, Brijesh Arora, Shripad Banavali, Sumeet Gujral
Journal: Blood (2015)
Multicenter Experience with Imatinib Mesylate in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients.
Authors: A.M. Carella, E. Lerma, E. Orlandi, M. Lazzarino, M. Annunziata, F. Ferrara, E. Pungolino, E. Morra, M. Miglino, M. Gobbi
Journal: Blood (2007)
Who should be performed perioperative chemotherapy in upper-tract urothelial cancer? Risk classification for selecting candidate using preoperative factors.
Authors: Kazuhiro Nagao, Ryo Inoue, Teruo Inamoto, Kiyoshi Takahara, Hiroaki Matsumoto, Yoshiaki Yamamoto, Keita Kobayashi, Shigeru Sakano, Haruhito Azuma, Hideyasu Matsuyama
Journal: Journal of Clinical Oncology (2015)

328 Background: The patients with advanced upper tract urothelial carcinoma (UTUC) have poor prognosis. Previous reports have not shown that neoadjuvant chemotherapy for UTUC improves patient survival and it is difficult to select appropriate candidates for neoadjuvant chemotherapy. We aimed to predict appropriate candidates for neoadjuvant chemotherapy. Methods: We reviewed the data of 536 patients with UTUC undergone total nephroureterctomy in the cohort of Yamaguchi Uro-Oncology Group (Group 1) and 150 cases in the cohort of Osaka Medical College (Group 2). We performed a multivariate analysis to the Group 1 to decide independent predictive factors and validated them in another cohort (Group 2). We evaluated the clinical significance of the predictive factors in cancer-specific survival (CSS) and overall survival (OS) between the cohort with and without perioperataive chemotherapy. Results: Multivariate analysis showed ≥cT3, cN+ and elevated CRP (≥0.31mg/dl) could become independent prognostic factors in Group 1, which showed 0.70 of AUC in predicting cancer death. We validated these factors in Group 2 and confirmed that they also showed 0.78 of AUC in predicting cancer death. Then, we divided the patients into 4 risk groups based on the number of the predictive factors: score 0 (202 cases), score 1 (152 cases), scores 2 (51 cases) and scores 3 (30 cases). Kaplan-Meier Curve showed that 5 year CSS in score 0, 1, 2, and 3 were 84.7%, 67.7%, 32.2% and 22.0%, respectively. Finally, we analyzed the difference in CSS and OS between the 138 cases with and 296 cases without perioperative chemotherapy. A significant difference in CSS and OS between the cases with and without perioperative chemotherapy was shown only in the cases with all the predictive factors: score 3. Additionally, fraction of patients with lymphovascular invasion of the surgical specimen were significantly increased with score advance. Conclusions: Survival in the patients with UTUC was predictable by preoperative factors. The patients with all the predictive factors, ≥cT3, cN+ and elevated CRP, were supposed to be the best candidates for neoadjuvant chemotherapy against UTUC.
Low Expression of IL-15 in Adult B-Lineage Acute Lymphoblastic Leukemia Is Associated with Central Nervous System Involvement at Initial Presentation.
Authors: Shuling Wu, Thomas Burmeister, Claudia Baldus, Stefen Schwartz, Michael Notter, Nicola Goekbuget, Dieter Hoelzer, Wolf K. Hofmann, Eckhard Thiel
Journal: Blood (2007)
Epigenetic Dysregulation of GATA1 but Not Downstream Notch Effectors is Involved in MDS Dyserythropoiesis.
Authors: Olaf Joachim Hopfer, Martina Komor, Claudia Freitag, Maximilian Mossner, Dieter Hoelzer, Eckhard Thiel, Wolf-Karsten Hofmann
Journal: Blood (2008)
Safety and efficacy of gemcitabine and trastuzumab in HER2-directed therapy pretreated patients with HER2-positive metastatic breast cancer: SBP-01 study.
Authors: Seiji Yoshitomi, Hisashi Tsuji, Masahiko Ikeda, Mitsuya Ito, Shoichiro Ohtani, Kenji Higaki, Teiri Sagawa, Kinya Matsuoka, Hiroshi Kawai, Daisuke Takabatake, Hiroyoshi Doihara, Tadahiko Shien, Naruto Taira, Yasuyuki Ohtawa, Shuichiro Maruyama, Hajime Hikino, Sayaka Fujii, Yutaka Yamamoto, Shozo Ohsumi, Fumikata Hara
Journal: Journal of Clinical Oncology (2015)

142 Background: Prognosis of HER2-positive metastatic breast cancer (MBC) has been dramatically improved by trastuzumab (Tmab). More recently, newer anti-HER2 agents such as lapatinib, pertuzumab and T-DM1 have prolonged survival. Despite the efficacy of these drugs, most patients develop progressive disease during or after treatment, and alternative anti-HER2 agents plus chemotherapies are required in subsequent lines of treatment. However, there are few evidence on efficacy of Tmab-containing regimens after disease progression. Gemcitabine (GEM) is non-cross resistant to anthracycline and taxane. Preclinical studies have shown that the combination of Tmab and GEM has synergistic effect against HER2-positive breast cancer cell lines. SBP-01 study assessed the efficacy and safety of the combination of Tamb and GEM in patients with HER2-positive MBC previously treated with anti-HER2 therapy. Methods: SBP-01 study included patients treated with one or more anti-HER2 directed regimens for MBC. Patients were administered with GEM 1250 mg/m 2 on days 1 and 8 of each 21-day cycle and Tmab 4mg/kg loading dose and then 2mg/kg weekly. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression free survival (PFS), overall survival, and safety. Results: Between June 2011 and June 2014, 35 patients were enrolled. Patients had ER positive tumor (37.1%), a median of 2 metastatic organ sites, visceral metastasis (80.0%), prior (neo) adjuvant Tmab (22.9%) and a median of 2 prior chemotherapy regimens for MBC. Previous HER2-directed drugs included Tmab (94.3%), lapatinib (37.1%), T-DM1 (8.6%) and pertuzumab (2.9%). ORR was 22.9% (95% CI, 8.6%-36.8%). Median PFS was 146 days. Patients with stable disease response received a median of 7 cycles (6-28 cycles) of treatment. Grade3/4 leukopenia (20.0%) and neutropenia (48.6%) were observed. All non-hematological toxicities were less than grade3. Conclusions: The Combination Tmab and GEM is effective and well-tolerated regimen for patients previously treated with HER2-directed therapy, and appears to make disease stable for long time period. Clinical trial information: UMIN000005881.
New onset facial swelling
Authors: Charlotte Cuddihy, Noelle O’Rourke
Journal: BMJ (2017)

A 64 year old woman presented to her general practitioner with a one week history of cough with green sputum. These symptoms were preceded by a two month history of worsening shortness of breath and swelling of her face, arms, neck, and breasts. Her family reported her face becoming “purple . . . like she’s going to burst.” Her medical history included hypertension and an episode of pneumonia four years earlier, and she had a smoking history of 40 pack years.

She was referred to the medical assessment unit. On examination, she had oedema and plethora of her face, arms, and upper chest, but no jugular venous distension or collateral vessels. There was no jaundice, anaemia, clubbing, cyanosis, or lymphadenopathy. Observations were unremarkable. Her airway was patent and the trachea central, with a respiratory rate of 17 breaths per minute (range 12-20 breaths per minute) and saturations of 98% on air. There was decreased air entry and dullness to percussion throughout the whole right lung. Cardiovascular examination was normal. Bloods on admission were white cell count 13.7×109/L (4.0-11.0x109/L), haemoglobin 112 g/L (115-165g/L), C reactive protein 139 mg/L(0-10mg/L) . Urea and electrolytes, liver function tests, and bone profile were normal. Chest radiography showed a large pleural effusion on the right. Urgent computed tomography (CT) with contrast showed a large mass lesion involving the mediastinum, which was completely compressing the diameter of the superior vena cava to a slit (fig 1⇓). …
High Levels of Protein C Are Determinated by PROCR H3 in a Dutch Family.
Authors: Maria Carolina Pintao, Sara Roshani, Marieke C.H. de Visser, Cris Tieken, Michael W.T. Tanck, Harry Roger Buller, Iris M Wichers, Joost C.M. Meijers, Saskia Middeldorp, Pieter H. Reitsma
Journal: Blood (2009)
Immune Thrombocytopenia Associated to Low-Dose Alemtuzumab Therapy in Chronic Lymphocytic Leukemia: A Single Retrospective Center Experience
Authors: Gianluigi Reda, Francesco Maura, Giuseppe Gritti, Daniele Vincenti, Mariarita Sciumé, Nicola Orofino, Anna Ines Gregorini, Cristina Bucelli, Francesca Binda, Francesca Guidotti, Alfonso Piciocchi, Francesco Rodeghiero, Antonino Neri, Agostino Cortelezzi
Journal: Blood (2012)